ArticleScientific reports2021

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.

Linda Vidarsdottir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.